Natural History of Thyroid Eye Disease

Thyroid ◽  
1998 ◽  
Vol 8 (5) ◽  
pp. 423-425 ◽  
Author(s):  
PETROS PERROS ◽  
PAT KENDALL-TAYLOR
Orbit ◽  
2020 ◽  
pp. 1-5
Author(s):  
Christopher Lo ◽  
Michael Yang ◽  
Daniel Rootman

Ophthalmology ◽  
2016 ◽  
Vol 123 (2) ◽  
pp. 425-433 ◽  
Author(s):  
Jeffrey P. Lienert ◽  
Laura Tarko ◽  
Miki Uchino ◽  
William G. Christen ◽  
Debra A. Schaumberg

2019 ◽  
Vol 104 (2) ◽  
pp. 254-259
Author(s):  
Dong Cheol Lee ◽  
Stephanie M Young ◽  
Yoon-Duck Kim ◽  
Kyung In Woo

AimsTo evaluate the natural course of upper eyelid retraction (UER) in patients with thyroid eye disease (TED) and factors affecting its course.MethodsRetrospective non-interventional cohort study in a single tertiary institution from March 2006 to March 2015 on patients with TED with (1) unilateral or bilateral UER within 6 months from initial presentation, and (2) no prior interventions nor surgical treatment for their UER. Main outcomes and measures were mean margin reflex distance 1 (MRD1) and factors associated with UER improvement.ResultsThere were a total of 61 patients and 81 eyes (41 unilateral and 20 bilateral UER). Mean age was 42.3±15.1 years. Mean MRD1 decreased from 6.1 mm at presentation to 4.8 mm at 12 months, and 4.4 mm at 24 months. The proportion of eyes with normalisation of lid height increased from 0% at presentation to 22.2% at 6 months, 37.0% at 12 months and 49.4% at 24 months. Mean time to normalisation of MRD1 was 18.0±12.4 months. A positive family history of TED was found to be associated with a 6.2 times lower likelihood of normalisation. Change in exophthalmometry, clinical activity score and thyroid-stimulating immunoglobulin were significantly correlated to change in MRD1 (p<0.05). There was no correlation between change in MRD1 and thyroid-stimulating hormone receptor antibodies.ConclusionAn improved knowledge of the natural history of UER in TED will allow us to better decide and evaluate the optimal management for such patients.


2019 ◽  
pp. 207-212
Author(s):  
Matthew J. Thurtell ◽  
Robert L. Tomsak

Thyroid eye disease is the most common cause of orbital disease encountered in clinical practice. It most often occurs in patients with Graves disease, but can also occur in the absence of thyroid dysfunction. In this chapter, we begin by reviewing the clinical features and natural history of thyroid eye disease. We next discuss the diagnostic evaluation of thyroid eye disease, including the roles of imaging and visual field testing. We then briefly review the differential diagnosis, which includes idiopathic orbital inflammation, orbital cellulitis, and carotid-cavernous fistula. Lastly, we discuss the management approach for thyroid eye disease. Many patients have only mild disease and can be managed with supportive treatments, such as artificial tears, prisms, and selenium supplementation. However, patients with moderate to severe thyroid eye disease often require more aggressive treatments, such as immunosuppression with systemic corticosteroids, orbital irradiation, and orbital decompression surgery.


2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Shannon Luu ◽  
Gloria Wu ◽  
Brian Leung ◽  
Donia Momen ◽  
Chap-Kay K Lau

Abstract Background: Thyroid eye disease is thought to present as proptosis and/or severe conjunctival chemosis. Severe dry eye disease and its symptoms of non-specific eye pain and foreign body sensation in the eye can be overlooked as an early biomarker of thyroid disease. New infrared imaging can be used to evaluate dry eye and eyelid gland anatomy. Infrared imaging and detailed history of thyroid eye symptoms may lead to subsequent testing of thyroid function and more referrals to thyroid specialists. Purpose: Using infrared photography to evaluate dry eye complaints in patients: do they have thyroid disease? Methods: A retrospective chart review (2017–2019) of patients with dry eyes, eyelid imaging with infrared photography and thyroid lab testing was performed. Infrared photography with 820 nm wavelength (Heidelberg Spectralis, Heidelberg, Germany). Percentage loss of Meibomian glands was identified for each eye, then analyzed, per patient. The control population consisted of patients with no dry eye complaints, no thyroid testing or thyroid history. Exclusion criteria: patients over the age of 90 years and patients with a history of glaucoma, diabetes, cataract surgery, and eyelid surgery. Age matching was done (±5 years). Results: n=48 patients, avg age=57.73 years (sd=16.81, range 21–85 years). Thyroid patients: n=24 patients, male=10, female=14, avg age= 57.12 years (sd=16.65, med=55.5, range 23–83 years). Controls: n=24 patients, male=9, female=15, avg age=58.33 years (sd=17.30, med=58, range 21–85 years). Loss of Meibomian glands: thyroid=40.94%, control=5.10% (p&lt;0.0001, t-test). Dry eye complaints: thyroid = 16/24, control = 0/24 (p&lt;0.0001, x2). Discussion: Meibomian glands are glands in the upper and lower eyelids. These glands provide the lipid component of the tear film, thus slowing the evaporation of the tears and stabilizing the tear film with each blink. Meibomian gland loss would explain the dry eye symptoms in an abnormal thyroid patient population. Infrared photography can be performed with a #87 camera lens filter (cost = $65). The loss of Meibomian glands may be an early sign for thyroid disease. Conclusion: Infrared photography may be helpful in identifying severe dry eye, thus leading to increased awareness of thyroid eye disease symptoms in our patients in ophthalmology, endocrinology, and primary care.


2019 ◽  
Vol 17 (3) ◽  
pp. 424-433 ◽  
Author(s):  
Michael T.M. Wang ◽  
Jennifer P. Craig

2021 ◽  
Vol 62 (11) ◽  
pp. 1553-1559
Author(s):  
Jungyul Park ◽  
Hee-young Choi

Purpose: To demonstrate the efficacy of subcutaneous tocilizumab (TCZ-SC) treatment for recalcitrant thyroid eye disease (TED) refractory to intravenous methylprednisolone (MP) and oral methotrexate (MTX).Case summary: (Case 1) A 52-year-old man, smoker, with hyperthyroidism presented with a 3-months history of TED. The initial clinical activity score (CAS) was 5 (total score of 7). High-dose intravenous MP and oral MTX failed to improve the symptoms. He was treated with four doses of 162 mg TCZ-SC at an interval of 2 weeks. Pre-treatment laboratory test results were within normal limits. CAS was reduced to 2 weeks after the final injection, and there were no recurrences during the 6-month follow-up. (Case 2) A 37-year-old woman, non-smoker, with a 3-months history of hyperthyroidism presented with conjunctival injection and upper eyelid erythema. The initial CAS was 4, and thyroid-stimulating immunoglobulin level was raised (475% of normal). The symptoms did not improve with 7.5 g intravenous MP and oral MTX. The patient was treated with 162 mg TCZ-SC. Pre-treatment laboratory test results were within normal limits. CAS was reduced to 1 after the final injection, and there were no recurrences during the 6-months follow-up.Conclusions: TCZ-SC improves symptoms of corticosteroid-resistant TED, and may be a reasonable option in recalcitrant TED cases. However, further studies are required to justify the use of TCZ-SC for TED.


Sign in / Sign up

Export Citation Format

Share Document